Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Phase 1/2 Unknown 50 enrolled Hongnan Mo

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.

Timeline

Start: 2016-06
Primary completion: 2020-09
Completion: 2020-09

Publications

Mo H, Liu P, Qin Y, He X, Han X, Yao J, Su W, Zhang S, Tang L, Zhao F, Gui L, Yang S, Yang J, Zhou S, Zhang Z, Shi Y. Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study. Chronic Dis Transl Med. 2021 Jun 24;7(3):190-198. doi: 10.1016/j.cdtm.2021.05.003. eCollection 2021 Sep.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	recombinant human thrombopoietin	Protein / enzyme biologic	300 iu/kg	—

Indications

No indication recorded.